

1 **Cohort Profile: Prospective Cohort to Study the COVID-19 Immune Response in**
2 **Retail Workers in Québec, Canada (CISACOV)**

3 *Authors:* Kim Santerre^{1*}, Mathieu Thériault^{1*}, Nicholas Brousseau², Samuel Rochette³,
4 Joelle N. Pelletier,^{4,5,6} Caroline Gilbert,¹ Jean-François Masson,^{4,7,8,9} Mariana Baz,¹ Denis
5 Boudreau,¹⁰ Sylvie Trottier¹

- 6 1. Département de microbiologie-infectiologie et d’immunologie, Centre de
7 recherche du centre hospitalier universitaire de Québec, Université Laval,
8 Québec, QC G1V 4G2, Canada
- 9 2. Biological Risks Department, Institut national de santé publique du Québec,
10 Québec, QC G1V 5B3, Canada
- 11 3. SR Scientific Writing Services, Brossard, QC J4Z 3C7, Canada
- 12 4. Department of Chemistry, Université de Montréal, Montréal, QC H2V 0B3,
13 Canada
- 14 5. Department of Biochemistry, Université de Montréal, Montréal, QC H2V 0B3,
15 Canada
- 16 6. PROTEO — The Québec Network for Research on Protein Function, Engineering,
17 and Applications, Québec, QC G1V 0A6, Canada
- 18 7. Quebec center for advanced materials, Université de Montréal, Montréal, QC
19 H3C 3J7, Canada
- 20 8. Regroupement québécois sur les matériaux de pointe, Université de Montréal,
21 Montréal, QC H3C 3J7, Canada

22 9. Centre interdisciplinaire de recherche sur le cerveau et l'apprentissage,

23 Université de Montréal, Montréal, QC H3C 3J7, Canada

24 10. Département de chimie et Centre d'optique, photonique et laser (COPL),

25 Université Laval, Québec, QC G1V 0A6, Canada

26 **Co-first authors*

27 **Corresponding author:**

28 Mariana Baz, PhD

29 E-mail : mariana.baz@crchudequebec.ulaval.ca

30 Tel: 418-525-4444 ext 48281

31 Mathieu Thériault, PhD

32 E-mail : mathieu.theriault@crchudequebec.ulaval.ca

33 Tel: 418-525-4444 ext 47992

34 **ABSTRACT**

35 *Purpose:* Retail workers are an understudied occupational group that may have been at
36 increased risk of contracting SARS-CoV-2 during the COVID-19 pandemic. Therefore, we
37 set up a longitudinal cohort of participants working in this sector to better document the
38 incidence of SARS-CoV-2 infection and the immune response to infection and/or
39 vaccination in this group.

40 *Participants:* A total of 304 participants were recruited between April 20, 2021 and
41 October 22, 2021. They were invited to attend three visits (each separated by ~12 weeks)
42 during which they provided blood samples and information on participant characteristics,
43 COVID-19 symptoms, and vaccination. An extension phase of two additional visits was
44 carried out between March 15th, 2022 and October 3rd, 2022 to document the impact of
45 the Omicron variant among the 198 participants who were still eligible for recruitment.
46 Participants were aged 18 to 75 and worked in grocery stores, hardware stores, bars or
47 restaurants within the Québec City metropolitan area (Canada). *Findings to date:* This
48 article describes participants' demographic, socioeconomic, behavioral, clinical and
49 occupational characteristics, and their COVID-19 symptoms (where applicable). It also
50 describes SARS-CoV-2 vaccination status and any SARS-CoV-2 diagnostic test (i.e., PCR or
51 rapid antigen) performed from the beginning of the pandemic until the last visit.

52 *Future plans:* The incidence of SARS-CoV-2 infections will be assessed. The immune
53 response (innate and acquired) to SARS-CoV-2 infection or vaccination will be studied

54 using a variety of techniques, including reference and experimental enzyme-linked
55 immunosorbent assays, microneutralization assays with live viruses, experimental
56 pseudoneutralization with an angiotensin-converting enzyme 2-spike assay, peripheral
57 blood mononuclear cells and neutrophil stimulation, and a proliferation assay based on
58 carboxyfluorescein diacetate succinimidyl ester.

59 *Registration:* Not applicable.

60 *Strengths and limitations*

- 61 • This cohort offers a comprehensive dataset to study the immune response to
62 SARS-CoV-2 infection or vaccination (alone), or hybrid immunity, as participants
63 provided information on a wide range of demographic, socioeconomic,
64 behavioral, clinical, and occupational variables. However, the low proportion of
65 racial minorities (i.e., 3.0%) limits the use of this cohort to study racial
66 determinants of immunity to SARS-CoV-2.
- 67 • This cohort focuses on workers in the food and retail service sector, an
68 understudied population at high risk of occupational exposure to infectious
69 agents.
- 70 • This study covered seven pandemic waves and thus captured a large number of
71 confirmed infections from different variants.
- 72 • Sample collection was initiated immediately prior to COVID-19 vaccine availability
73 for this population and thus captured successive vaccination campaigns over 17
74 months.

- 75 • In keeping with the study design, none of the participants had severe COVID-19
76 disease requiring hospitalization at baseline, and none of the COVID-19 illnesses
77 that occurred during the study required hospitalization; this cohort may not,
78 therefore, be used to study the immune response leading to severe health
79 outcomes, but is appropriate to study the immune response to mild SARS-CoV-2
80 infections.
- 81 • Nearly 1300 blood samples were collected; furthermore, only 13 out of 304 (4.3%)
82 participants withdrew before attending all three initial visits, and 4 out of 198
83 (2.0%) participants who remained eligible in the extension phase withdrew before
84 attending the fifth visit. A series of at least 5 blood samples drawn over 48 weeks
85 is therefore available for most participants.

86 INTRODUCTION

87 During the SARS-CoV-2 pandemic, workers with client-facing duties were considered
88 to be at greater risk of infection than those who worked remotely.¹⁻³ Although most
89 studies have focused on healthcare workers (HCW),^{4 5} many non-HCWs were also
90 considered to be at risk due to their occupational exposure.^{6 7}

91 Workers in the food and retail industry are an understudied occupational group that
92 may have been at greater risk of contracting SARS-CoV-2. These workers often have
93 below-average incomes, face precarious employment conditions and lack benefit
94 packages to cover health-related absenteeism. At the beginning of the pandemic, these
95 workers often lacked the training and the access to protective equipment used by HCWs
96 to reduce exposure.⁸ However, risk is likely to vary from one sector to another. For
97 example, grocery stores were considered an essential service and therefore remained
98 open throughout the pandemic, with public health measures (e.g., mask wearing) being
99 enforced and generally well respected. In contrast, restaurants and bars were
100 intermittently opened and closed by health authorities over the same period, and public
101 health measures were more difficult to enforce due to the intrinsically social nature of
102 these businesses and their main purpose — the consumption of food and drink — that
103 precluded continuous mask wearing.

104 Compelling evidence now confirms that the risk of occupational exposure is high for
105 these workers. In a serological survey conducted in New York City prior to the approval of
106 the first COVID-19 vaccine, the seroprevalence of anti-spike antibodies was higher among

107 grocery store and restaurant workers than in most subgroups of HCWs.¹ In another
108 serosurvey conducted in Switzerland, kitchen staff and grocery store workers exhibited
109 an above-average seroprevalence compared to other essential workers.⁹ In the
110 Netherlands, individuals working in the hospitality sector were more likely to have a
111 positive PCR test result than those working in non-close-contact occupations.¹⁰ In Japan,
112 restaurants and bars were the second most common setting of SARS-CoV-2 outbreaks
113 after healthcare facilities.^{7 11}

114 To date, no thorough investigation of SARS-CoV-2 exposure has been conducted
115 among Canadian workers in grocery stores, hardware stores, bars or restaurants.^{12 13} Such
116 an investigation could help better prepare health authorities when implementing future
117 measures, including the designation of priority groups for vaccination, and mandatory
118 lockdowns in these sectors. Accordingly, we set up a longitudinal cohort that investigated
119 the incidence of COVID-19 and the humoral and cellular immunity (innate and acquired)
120 to SARS-CoV-2 in these workers. This article describes the experimental design of the
121 project and the cohort of participants.

122 **COHORT DESCRIPTION**

123 *Participants and setting*

124 Eligibility criteria included the following: (1) providing informed consent; (2) age ≥ 18
125 years; (3) working either on a full-time or part-time basis in a grocery store, hardware
126 store, bar or restaurant located in the administrative regions of Capitale-Nationale and
127 Chaudière-Appalaches that include and surround the area of Québec City, Canada; (4)
128 having a public-facing role in daily work-related activities; (5) having worked ≥ 20 full days
129 between February 1st, 2020 and the first visit; and (6) having no history of hospitalization
130 due to COVID-19.

131 Participants were recruited using a variety of strategies: 1) an online recruitment
132 campaign conducted by a student-run communication agency; 2) email invitations to
133 members of partner union organizations - *Confédération des syndicats nationaux* (CSN)
134 and to sectoral organizations of hardware store workers - *Association Québécoise de la*
135 *quincaillerie et des matériaux de construction* (AQMAT); and 3) email information to all
136 students and employees at *Université Laval* and the *Centre Hospitalier Universitaire de*
137 *Québec* in order to publicize the study.

138 *Design and procedures*

139 The study was initially designed as a prospective cohort study with three sampling
140 visits, each separated by 12 ± 2 weeks, between April 20th, 2021 and October 3rd, 2022. In
141 response to the emergence of Omicron, an extension of two additional visits was
142 proposed to the participants who were still eligible for recruitment. An additional COVID-

143 19 visit (VCoV) was also planned shortly after the occurrence of any SARS-CoV-2 infection
144 during the study period (Figure 1).

145 At the first visit (“V1”), participants signed an informed consent form and were then
146 interviewed by trained nurses to obtain information on demographic, socioeconomic,
147 behavioral, clinical and occupational variables (Table 1). The questionnaires were adapted
148 from those suggested by our funding body, the COVID Immunity Task Force (CITF).¹⁴ At or
149 after the third visit (“V3”), eligible participants received information about the extension
150 of the study and signed a new informed consent if they were interested in participating.

151 At the second (“V2”), third (“V3”), fourth (“V4”) and fifth visits (“V5”), participants
152 completed an abridged version of the V1 questionnaire that focused the COVID-19
153 vaccines that they received and SARS-CoV-2 symptoms, diagnosis, exposure and
154 associated risk factors (Table 1). Blood was drawn to study humoral immunity (i.e., at V1
155 to V5) and cellular immunity (i.e., at V1, V3, and V5) to SARS-CoV-2. Additional PCR tests
156 were carried out at V4 and V5 to detect asymptomatic carriers.

157 The VCoV visits took place at a median time of 15 days (10 to 42 days) after the onset
158 of symptoms. Blood was drawn to study humoral and cellular immunity and a
159 questionnaire focusing exclusively on SARS-CoV-2 diagnosis and symptoms was
160 completed at that visit.

161 *Study exposures and follow-up*

162 The two main exposures of the study were SARS-CoV-2 infection, defined as a
163 positive test result for SARS-CoV-2 (PCR or antigen detection), and participants’

164 vaccination status. Participants were asked about possible or confirmed SARS-CoV-2
165 infection (i.e., symptoms, diagnostic test, test date and test result) and their SARS-CoV-2
166 vaccination history (i.e., number of doses, date of vaccination, type of vaccine) since the
167 beginning of the pandemic at V1, and since the last visit (at V2 to V5). Positive SARS-CoV-
168 2 test results were therefore captured from the beginning of the pandemic until the
169 earliest among the last visit, withdrawal from the study, or loss of eligibility.

170 *Study outcome*

171 The primary outcomes were vaccine- and infection-induced immunity. We also
172 explored the humoral immunity, using different techniques and antigens, and the cellular
173 immunity (innate and acquired).

174 *Confidentiality and data storage*

175 This study was approved by the « *Comité d'éthique de la recherche du CHU de Québec*
176 – *Université Laval* » (registration number 2021-5744). A unique, anonymized identifier
177 was assigned to each participant and used to store the data and the samples. The samples
178 will be stored for up to 10 years, and the data for at least 15 years.

179 *Patient and public involvement statement*

180 No public stakeholders were involved in establishing and designing this cohort.

181 *Participant characteristics*

182 Overall, 304 individuals were initially recruited to attend the three first visits from
183 April 20th, 2021 to May 9th, 2022. The cohort included 149 (49.0%) restaurant/bar

184 workers, 112 (36.8%) grocery store workers, and 43 (14.1%) hardware store workers.
185 With the emergence of Omicron, 198 participants who at the time of ethic approval were
186 still within the recruiting window, were included for two additional visits (12±4 weeks
187 apart) between March 15th, 2022 and October 3rd, 2022. Only 13 out of 304 (4.3%)
188 withdrew before V3, and only 4 more out of 198 (2.0%) withdrew at V5, resulting in a
189 series of at least 5 blood samples drawn over 48 weeks for most participants.

190 On average, participants were aged 41.3 years in the overall cohort (Table 2).
191 Specifically, restaurants/bar workers were on average 37.2 years old, grocery store
192 workers 44.2 and hardware store workers 48.2. Female participants represented 57.9%
193 of the cohort. Overall, 96.7% self-identified as White, 1.6% as Asian, 1.0% as Latino
194 American, and 0.7% as Black. The low proportion of racial minorities (i.e., 3.3%) is
195 consistent with the size of the visible minority population in the Québec City metropolitan
196 area (i.e., 4.9% according to census).¹⁵ Levels of education varied: 39.4% reported having
197 a high school diploma or vocational certificate, 33.2% a higher education certificate and
198 22.7% at least a university degree. In total, 76.0% of participants resided in the Capitale-
199 Nationale administrative region, the remainder residing in the Chaudière-Appalaches
200 administrative region (Table 3). Most (i.e., 62.2%) lived alone or with one other person,
201 23.0% lived with children (<18 years), 15.5% with HCWs and 7.6% with teachers or
202 kindergarten workers. These distributions were similar within each occupational group.

203 According to body mass index (BMI), 41.1% of the participants had a healthy weight
204 (i.e., BMI=18.5 to 24.9 kg/m²), 27.0% were overweight (BMI=25.0 to 29.9 kg/m²) and

205 30.6% were obese (BMI ≥ 30 kg/m²) (Table 4). Only 1.3% were considered underweight
206 (BMI <18.5 kg/m²). Cigarette (i.e., tobacco) use was reported by 17.4% of the participants
207 and e-cigarette use by 7.9%. About half (i.e., 47.7%) of participants reported having at
208 least one comorbidity. Hardware store workers had more comorbidities, probably
209 because they were slightly older (on average). Overall, 17.1% reported usually receiving
210 an annual influenza vaccine (13.8% in the year prior to the first visit).

211 Approximately half (i.e., 53.6%) of the participants reported working on average
212 more than 30 hours per week (Table 5). Most (88.8%) had attended at least one gathering
213 of 10 or more persons during the study period, and 40.8% reported attending more than
214 10 such gatherings. The predominant mode of transportation was by car (88%), followed
215 by bus (12.8%) and walking (9.2%). Traveling outside the province of Québec was reported
216 by 47.0% of the participants, with 25.7% travelling within Canada, 14.8% to the United
217 States, and 27.6% elsewhere. The distribution of participants in each occupational group
218 was similar for the workplace region, mode of transportation and travelling, but differed
219 for the weekly hours worked and the number of gatherings attended.

220 Overall, 98.7% of the participants reported wearing a mask at work, indicating
221 excellent adherence to this measure (Table 6). Other measures, such as handwashing
222 (98.4%), distancing (70.1%) and the use of Plexiglas dividers (77.3%) were also frequent.
223 The use of gloves (6.9%) and face-shields (10.5%), which were not extensively promoted
224 by the regional public health authorities, were less frequent. Outside work, all
225 participants reported wearing a mask in public (100.0%); most avoided usual salutations

226 (85.2%), practiced social distancing (84.2%) and avoided contact with vulnerable persons
227 (83.6%) and crowded places (76.6%). Most participants reported washing their hands
228 when dirty (96.7%), after using the bathroom (97.7%), when arriving at (92.1%) and
229 leaving the workplace (71.7%), before eating (87.8%) and after handling trash (79.6%). In
230 general, adherence to these measures was consistently lower among restaurant and bar
231 workers, possibly because of the nature of their work or their younger age (on average).

232 **FINDINGS TO DATE**

233 *SARS-CoV-2 infection*

234 Overall, 168 positive tests were reported in 121 participants throughout the study
235 period (Table 7). Of these tests, 117 were the first to yield a positive result as reported by
236 the participants; 40 (performed by 37 participants) were additional tests with 32
237 considered follow-up tests (<90 days since previous test) and 8 detecting a second or third
238 infection (>90 days since previous test). The remaining 11 (including four first-ever
239 positives) were PCR tests performed as per protocol at V4 and V5 among asymptomatic
240 or pre-symptomatic individuals. In addition, 29 participants reported 31 suspected
241 COVID-19 infections based on their symptoms, although not confirmed by a PCR or
242 antigen detection test.

243 *SARS-CoV-2-related symptoms*

244 Among the 117 participants with a first confirmed SARS-CoV-2 infection, 94.9%
245 reported ≥ 1 symptom at the time of testing (Table 8). Each individual symptom was
246 experienced by $\geq 47.9\%$ of participants, except for diarrhea (13.7%) and loss of smell or

247 taste (22.2%), a pattern consistent with prior studies.¹⁶⁻¹⁸ These distributions were similar
248 within each occupational group.

249 Vaccination for SARS-CoV-2

250 The participants were vaccinated according to local government recommendations
251 with the vaccines approved by Canadian health authorities. The COVID-19 vaccines
252 available were monovalent Comirnaty (Pfizer-BioNTech), Spikevax (Moderna) and
253 Vaxzevria (AstraZeneca), which each required two doses to complete the primary series.
254 Hardware store workers were the most highly vaccinated occupational group, 100% of
255 them having received two doses by February 2022 (Figure 2). By the end of the study (i.e.,
256 last visit between May 10th, 2022 and October 3rd, 2022), nearly 70% of all participants
257 had received at least one booster dose.

258 At the time of testing positive, 17.9% of the participants had received no vaccine
259 dose, 0.9% had received a single dose of vaccine, 38.4% had received two, 39.3% had
260 received three, and 3.4% had received four (Table 9). In participants who tested positive
261 and had received at least two vaccine doses, all infections occurred after the 4th wave,
262 when the Omicron variant was predominant.

263 *Blood sample bank to study infection-induced, vaccine-induced, and hybrid immunity*

264 Overall, 1299 blood samples were collected, including 304 (23.4%) at V1, 297 (22.9%)
265 at V2, 291 (22.4%) at V3, 198 (15.2%) at V4, 194 (15.0%) at V5, and 15 (1.2%) at additional
266 visits (i.e., VCoV). In total, 69.2% of the blood samples were drawn from vaccinated
267 participants with no known history of SARS-CoV-2 infection, 23.1% from vaccinated and

268 previously infected participants, 6.9% from unvaccinated participants with no known
269 history of SARS-CoV-2 infection, and 11 (0.8%) from previously infected and unvaccinated
270 participants (Table 10).

271 **STRENGTHS AND LIMITATIONS**

272 We set up a cohort of 304 participants to conduct a longitudinal study of COVID-19
273 immunity among food and retail workers who lived and worked within the greater
274 Québec City metropolitan region. The participants provided information on a wide range
275 of demographic, socioeconomic, behavioral, clinical and occupational variables. The study
276 covered seven waves of COVID-19 infection, including those dominated by the Alpha,
277 Delta, and Omicron variants, thus capturing a relatively large number of epidemiological
278 periods and infections. In addition, the blood samples were collected at each scheduled
279 visit regardless of participants' infection or vaccination history, thus enabling the study of
280 infection-induced, vaccine-induced and hybrid immunity in this extensively characterized
281 cohort. Moreover, few participants withdrew from the study before the end of the initial
282 (i.e., V1-V3) and extension phases (i.e., V4-V5), resulting in complete series of at least 5
283 samples for most participants.

284 A total of 117 first (ever) COVID-19 infections were reported, and most occurred
285 between December 5th, 2021 and October 3rd, 2022, consistent with the emergence of
286 the highly contagious Omicron variant. In the present study, vaccine coverage was high:
287 by the time Omicron had emerged, nearly 95% of the participants had already received
288 two vaccine doses (primary series). This high rate of vaccination may be because retail

289 workers considered themselves at higher risk of SARS-CoV-2 exposure than the general
290 population and were thus more willing to get vaccinated and reduce their risk of infection.

291 Some limitations must be considered when interpreting our results. Per the study
292 design, none of the participants had previously experienced a severe COVID-19 illness
293 that required hospitalization. Therefore, the cohort may not be used to study the immune
294 response that leads to severe health outcomes, but is appropriate to study the immune
295 response to mild COVID-19 illness. Furthermore, our study was not designed to infer a
296 causal relationship between a worker's occupational sector and the risk of SARS-CoV-2
297 infection, such that confounders probably explain part of the differences among
298 occupational groups. For example, relative to hardware store workers, grocery store
299 workers were younger (i.e., mean age: 44.2 vs. 48.2 years), included more overweight or
300 obese participants (i.e., 72.3% vs. 46.5%), and lived in more crowded households (i.e.,
301 proportion with ≥ 3 residents: 49.1% vs. 25.6%), which may have predisposed them to
302 infection. Another limitation is that the cohort may have been subject to a sampling bias
303 as there may be less vaccine hesitancy among people willing to participate in a scientific
304 study. Hence, the study participants may not be representative of the overall population
305 of workers in these sectors. This is suggested by the 5% to 7% higher vaccination coverage
306 for the second dose as of fall 2021 compared to the general population of the province of
307 Québec.

308 The low proportion of racial minorities (i.e., 3.0%) also limits the use of this cohort to
309 study racial determinants of immunity to SARS-CoV-2. In addition, participant responses

310 may have been affected by a memory bias, particularly for those whose last infection
311 occurred months before V1. Moreover, few samples were drawn from unvaccinated and
312 previously infected participants, so that the cohort may be of limited use to study
313 immunity induced by infection alone. The high vaccination coverage also made it
314 impossible to assess the impact of vaccination on the risk of infection, since, at any given
315 time, most participants had been vaccinated. Lastly, our study may have underestimated
316 the incidence of SARS-CoV-2 infection since most infections occurred during the Omicron
317 wave, when access to PCR-based screening was limited in Québec (and only less sensitive
318 antigen detection tests were available). The serology data of these samples will shed light
319 on this question.

320 **COLLABORATION**

321 More detailed, participant-level information is publicly available on an online platform
322 developed by Maelstrom Research.¹⁹ Researchers with other enquiries or collaboration
323 proposals may contact Sylvie Trottier — the principal investigator in charge of setting up
324 the cohort — at sylvie.trottier@crchudequebec.ulaval.ca. Data on participants' immune
325 responses to SARS-CoV-2 infection and vaccination will be shared through peer-reviewed
326 publications.

327 **Funding:** This project is being supported by funding from the Public Health Agency of
328 Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity
329 Task Force (grant number: 2021-HQ-000134).

330 **Competing interests statement:** Nothing to declare.

331 **Data sharing statement:** All participant-level information is publicly available on an online
332 platform developed by Maelstrom Research.

333 **Author contributions:** The co-principal investigators of the study were DB and ST, who
334 conceived the study and led the proposal. Protocol design and development team: J.N.P.,
335 C.G., J.-F.M., M.B., D.B., and S.T. K.S. constructed the data base, coordinated the study
336 and contributed to the data analysis. M.T. did the maintenance and the development of
337 the data base, the cleaning of the data and contributed to data analysis. N.B. oversaw
338 the data analysis. S.R. participated to data analysis and wrote the first draft of the
339 manuscript. All authors critically reviewed and approved the final manuscript.

340 **Acknowledgements:** The authors thank the participants and all the staff involved in
341 planning and preparation of this study. David Simonyan helped with statistical analysis. A
342 special thank you to our partners: CSN Federation of Commerce and AQMAT.

343 **ORCID iDs**

344 Sylvie Trottier <https://orcid.org/0000-0002-3986-5146>

345 Denis Boudreau <https://orcid.org/0000-0001-5152-2464>

346 Caroline Gilbert <https://orcid.org/0000-0003-2722-1180>

347 Jean-Francois Masson <https://orcid.org/0000-0002-0101-0468>

348 Mariana Baz <https://orcid.org/0000-0002-1230-0735>

349 Joelle Pelletier <https://orcid.org/0000-0002-2934-6940>

350 Mathieu Thériault <https://orcid.org/0000-0002-7293-7623>

351 REFERENCES

- 352 1. Pathela P, Crawley A, Weiss D, et al. Seroprevalence of Severe Acute Respiratory
353 Syndrome Coronavirus 2 Following the Largest Initial Epidemic Wave in the
354 United States: Findings From New York City, 13 May to 21 July 2020. *J Infect Dis*
355 2021;224(2):196-206. doi: 10.1093/infdis/jiab200
- 356 2. Feehan AK, Velasco C, Fort D, et al. Racial and Workplace Disparities in
357 Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA. *Emerg Infect Dis*
358 2021;27(1) doi: 10.3201/eid2701.203808 [published Online First: 20201110]
- 359 3. Sim MR. The COVID-19 pandemic: major risks to healthcare and other workers on the
360 front line. *Occup Environ Med* 2020;77(5):281-82. doi: 10.1136/oemed-2020-
361 106567 [published Online First: 20200401]
- 362 4. Gomez-Ochoa SA, Franco OH, Rojas LZ, et al. COVID-19 in Health-Care Workers: A
363 Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical
364 Characteristics, and Outcomes. *Am J Epidemiol* 2021;190(1):161-75. doi:
365 10.1093/aje/kwaa191
- 366 5. Gholami M, Fawad I, Shadan S, et al. COVID-19 and healthcare workers: A systematic
367 review and meta-analysis. *Int J Infect Dis* 2021;104:335-46. doi:
368 10.1016/j.ijid.2021.01.013 [published Online First: 20210111]
- 369 6. Boucher E, Cao C, D'Mello S, et al. Occupation and SARS-CoV-2 seroprevalence
370 studies: a systematic review. *BMJ Open* 2023;13(2):e063771. doi:
371 10.1136/bmjopen-2022-063771 [published Online First: 20230228]
- 372 7. Vachon MS, Demmer RT, Yendell S, et al. SARS-CoV-2 Seroprevalence Survey in
373 Grocery Store Workers-Minnesota, 2020-2021. *Int J Environ Res Public Health*
374 2022;19(6) doi: 10.3390/ijerph19063501 [published Online First: 20220316]
- 375 8. Parks CA, Nugent NB, Fleischhacker SE, et al. Food System Workers are the
376 Unexpected but Under Protected COVID Heroes. *J Nutr* 2020;150(8):2006-08. doi:
377 10.1093/jn/nxaa173
- 378 9. Stringhini S, Zaballa ME, Pullen N, et al. Large variation in anti-SARS-CoV-2 antibody
379 prevalence among essential workers in Geneva, Switzerland. *Nat Commun*
380 2021;12(1):3455. doi: 10.1038/s41467-021-23796-4 [published Online First:
381 20210608]
- 382 10. de Gier B, de Oliveira Bressane Lima P, van Gaalen RD, et al. Occupation- and age-
383 associated risk of SARS-CoV-2 test positivity, the Netherlands, June to October
384 2020. *Euro Surveill* 2020;25(50) doi: 10.2807/1560-7917.ES.2020.25.50.2001884
- 385 11. Furuse Y, Sando E, Tsuchiya N, et al. Clusters of Coronavirus Disease in Communities,
386 Japan, January-April 2020. *Emerg Infect Dis* 2020;26(9) doi:
387 10.3201/eid2609.202272 [published Online First: 20200610]
- 388 12. Decarie Y, Michaud PC. Counting the Dead: COVID-19 and Mortality in Quebec and
389 British Columbia During the First Wave. *Can Stud Popul* 2021;48(2-3):139-64.
390 doi: 10.1007/s42650-021-00053-z [published Online First: 20210917]
- 391 13. Shim E. Regional Variability in COVID-19 Case Fatality Rate in Canada, February-
392 December 2020. *Int J Environ Res Public Health* 2021;18(4) doi:
393 10.3390/ijerph18041839 [published Online First: 20210214]

- 394 14. COVID-19 Immunity Task Force standardized core survey data elements [Available
395 from: [https://www.covid19immunitytaskforce.ca/covid-19-immunity-task-force-](https://www.covid19immunitytaskforce.ca/covid-19-immunity-task-force-releases-standardized-core-survey-data-elements/)
396 [releases-standardized-core-survey-data-elements/](https://www.covid19immunitytaskforce.ca/covid-19-immunity-task-force-releases-standardized-core-survey-data-elements/) accessed February 15th, 2023
397 2023.
- 398 15. Census profile, 2016 census, Québec City [Available from:
399 [https://www12.statcan.gc.ca/census-recensement/2016/dp-](https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/details/page.cfm?Lang=E&Geo1=CSD&Code1=2423027&Geo2=CD&Code2=2423&Data=Count&SearchText=quebec&SearchType=Begins&SearchPR=01&B1=All&TABID=1)
400 [pd/prof/details/page.cfm?Lang=E&Geo1=CSD&Code1=2423027&Geo2=CD&C](https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/details/page.cfm?Lang=E&Geo1=CSD&Code1=2423027&Geo2=CD&Code2=2423&Data=Count&SearchText=quebec&SearchType=Begins&SearchPR=01&B1=All&TABID=1)
401 [ode2=2423&Data=Count&SearchText=quebec&SearchType=Begins&SearchPR](https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/details/page.cfm?Lang=E&Geo1=CSD&Code1=2423027&Geo2=CD&Code2=2423&Data=Count&SearchText=quebec&SearchType=Begins&SearchPR=01&B1=All&TABID=1)
402 [=01&B1=All&TABID=1](https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/details/page.cfm?Lang=E&Geo1=CSD&Code1=2423027&Geo2=CD&Code2=2423&Data=Count&SearchText=quebec&SearchType=Begins&SearchPR=01&B1=All&TABID=1) accessed February 16th, 2023.
- 403 16. Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3062 COVID-19 patients: A meta-
404 analysis. *J Med Virol* 2020;92(10):1902-14. doi: 10.1002/jmv.25884 [published
405 Online First: 20200624]
- 406 17. Burke RM, Killerby ME, Newton S, et al. Symptom Profiles of a Convenience Sample
407 of Patients with COVID-19 - United States, January-April 2020. *MMWR Morb*
408 *Mortal Wkly Rep* 2020;69(28):904-08. doi: 10.15585/mmwr.mm6928a2 [published
409 Online First: 20200717]
- 410 18. Government C. COVID-19 signs, symptoms and severity of disease: A clinician guide.
411 [Available from: [https://www.canada.ca/en/public-health/services/diseases/2019-](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/signs-symptoms-severity.html)
412 [novel-coronavirus-infection/guidance-documents/signs-symptoms-severity.html](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/signs-symptoms-severity.html).
- 413 19. Boudreau DT, Sylvie; Masson, Jean-François; Baz Etchebarne, Mariana; Gilbert,
414 Caroline; Pelletier, Joëlle;. CISACOV investigators. Cellular Immunity and
415 Seroprevalence of Antibodies against SARS-CoV-2: Characterisation of Three
416 Populations of Food Workers. , 2021-2022.
- 417 20. Canada Go. COVID-19 vaccination in Canada: Government of Canada; 2023 [updated
418 2023-03-03. Available from: [https://health-infobase.canada.ca/covid-](https://health-infobase.canada.ca/covid-19/vaccination-coverage/)
419 [19/vaccination-coverage/](https://health-infobase.canada.ca/covid-19/vaccination-coverage/).

420

421 **TABLES AND FIGURES**

422 **Table 1. Participant visits**

	Visit 1 N=304	Visit 2 N=297	Visit N=291	Visit 4 N=198	Visit 5 N=194	COVID-19 visit (VCoV) N=15
Retention	100%	98%	96%	100%	98%	-
Eligibility assessment	X			X		
Consent form	X			X		
Participant characteristics						
Demographic data	X					
Household data	X					
Clinical data	X					
Occupational data	X	X	X	X	X	X
Retrospective questionnaire form						
COVID-19 positive tests & symptoms	X	X	X	X	X	X
Vaccine status	X	X	X	X	X	X
Cross-section interventions						
Humoral immunity blood samples	X	X	X	X	X	X
Cellular immunity blood samples	X		X		X	X
COVID-19 PCR test at visit				X	X	

423

424 **Table 2. Detailed demographics of study participants at the first visit**

	Overall study population		Restaurant/bar workers		Grocery store workers		Hardware store workers	
	Total (N=304)	COVID-19 ¹ (N=117)	Total (N=149)	COVID-19 ¹ (N=62)	Total (N=112)	COVID-19 ¹ (N=42)	Total (N=43)	COVID-19 ¹ (N=13)
Age (years), Mean±SD	41.3 ± 15.9	39.6 ± 14.6	37.2 ± 14.8	36.2 ± 14.3	44.2 ± 15.3	42.4 ± 14.1	48.2 ± 17.3	46.5 ± 14.6
Age groups, N (%)								
18-59	257 (84.5%)	106 (90.6%)	135 (90.6%)	57 (91.9%)	93 (83.0%)	37 (88.1%)	29 (67.4%)	12 (92.3%)
60-75	47 (15.5%)	11 (9.4%)	14 (9.4%)	5 (8.1%)	19 (17.0%)	5 (11.9%)	14 (32.6%)	1 (7.7%)
Sex, N (%)								
Female	176 (57.9%)	72 (61.5%)	95 (63.8%)	39 (62.9%)	57 (50.9%)	25 (59.5%)	24 (55.8%)	8 (61.5%)
Male	128 (42.1%)	45 (38.5%)	54 (36.2%)	23 (37.1%)	55 (49.1%)	17 (40.5%)	19 (44.2%)	5 (38.5%)
Race/ethnicity,² N (%)								
White	294 (96.7%)	114 (97.4%)	142 (95.3%)	61 (98.4%)	109 (97.3%)	40 (95.2%)	43 (100.0%)	13 (100.0%)
Asian	5 (1.6%)	0 (0.0%)	4 (2.7%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Black	2 (0.7%)	2 (1.7%)	0 (0.0%)	0 (0.0%)	2 (1.8%)	2 (4.8%)	0 (0.0%)	0 (0.0%)
Latino American	3 (1.0%)	1 (0.9%)	3 (2.0%)	1 (1.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Educational attainment, N (%)								
Less than high school	14 (4.6%)	3 (2.6%)	4 (2.7%)	2 (3.2%)	9 (8.0%)	0 (0.0%)	1 (2.3%)	1 (7.7%)
High school	79 (26.0%)	27 (23.1%)	42 (28.2%)	14 (22.6%)	23 (20.5%)	7 (16.7%)	14 (32.6%)	6 (46.2%)
Professional certificate	41 (13.5%)	13 (11.1%)	19 (12.8%)	6 (9.7%)	16 (14.3%)	6 (14.3%)	6 (14.0%)	1 (7.7%)
CEGEP and college certificate	101 (33.2%)	45 (38.5%)	51 (34.2%)	26 (41.9%)	35 (31.3%)	14 (33.3%)	15 (34.9%)	5 (38.5%)
University baccalaureate	54 (17.8%)	22 (18.8%)	28 (18.8%)	12 (19.4%)	21 (18.8%)	10 (23.8%)	5 (11.6%)	0 (0.0%)
Graduate studies	15 (4.9%)	7 (6.0%)	5 (3.4%)	2 (3.2%)	8 (7.1%)	5 (11.9%)	2 (4.7%)	0 (0.0%)

425 Abbreviations: CEGEP = General and professional teaching college

426 Notes:

427 1. Subset of participants who contracted COVID-19 at least once during the study period.

428 2. Self-reported by study participants

429 **Table 3. Household characteristics of the participants at the first visit**

	Overall study population		Restaurant/bar workers		Grocery store workers		Hardware store workers	
	Total (N=304)	COVID-19 ¹ (N=117)	Total (N=149)	COVID-19 ¹ (N=62)	Total (N=112)	COVID-19 ¹ (N=42)	Total (N=43)	COVID-19 ¹ (N=13)
Region, N (%)								
Capitale-Nationale	231 (76,0%)	91 (77,8%)	112 (75,2%)	45 (72,6%)	86 (76,8%)	35 (83,3%)	33 (76,7%)	11 (84,6%)
Chaudière-Appalaches	73 (24,0%)	26 (22,2%)	37 (24,8%)	17 (27,4%)	26 (23,2%)	7 (16,7%)	10 (23,3%)	2 (15,4%)
Household size, N (%)								
1-2 residents	189 (62,2%)	76 (65,0%)	100 (67,1%)	48 (77,4%)	57 (50,9%)	19 (45,2%)	32 (74,4%)	9 (69,2%)
3-4 residents	93 (30,6%)	32 (27,4%)	36 (24,2%)	10 (16,1%)	48 (42,9%)	19 (45,2%)	9 (20,9%)	3 (23,1%)
≥5 residents	22 (7,2%)	9 (7,7%)	13 (8,7%)	4 (6,5%)	7 (6,3%)	4 (9,5%)	2 (4,7%)	1 (7,7%)
Co-residents, N (%)								
Underage (<18)	70 (23,0%)	29 (24,8%)	35 (23,5%)	12 (19,4%)	29 (25,9%)	14 (33,3%)	6 (14,0%)	3 (23,1%)
Healthcare worker	47 (15,5%)	17 (14,5%)	23 (15,4%)	9 (14,5%)	18 (16,1%)	5 (11,9%)	6 (14,0%)	3 (23,1%)
Kindergarden worker	10 (3,3%)	3 (2,6%)	5 (3,4%)	1 (1,6%)	5 (4,5%)	2 (4,8%)	0 (0,0%)	0 (0,0%)
Teacher	13 (4,3%)	7 (6,0%)	9 (6,0%)	4 (6,5%)	4 (3,6%)	3 (7,1%)	0 (0,0%)	0 (0,0%)
Household bedroom, N (%)								
0-2	158 (52,0%)	66 (56,4%)	90 (60,4%)	41 (66,1%)	49 (43,8%)	19 (45,2%)	19 (44,2%)	6 (46,2%)
≥3	146 (48,0%)	51 (43,6%)	59 (39,6%)	21 (33,9%)	63 (56,3%)	23 (54,8%)	24 (55,8%)	7 (53,8%)

430 Notes:

431 1. Subset of participants who contracted COVID-19 had least once during the study period.

432

433

434 **Table 4. Clinical characteristics of study participants at the first visit**

	Overall study population		Restaurant/bar workers		Grocery store workers		Hardware store workers	
	Total (N=304)	COVID-19 ¹ (N=117)	Total (N=149)	COVID-19 ¹ (N=62)	Total (N=112)	COVID-19 ¹ (N=42)	Total (N=43)	COVID-19 ¹ (N=13)
BMI scores, Mean±SD	27,3 ± 6,1	27,5 ± 6,4	27,0 ± 6,9	26,83 ± 6,7	28,1 ± 5,3	27,94 ± 5,2	26,3 ± 5,3	27,51 ± 6,6
BMI categories, N (%)								
<18.5 (underweight)	4 (1,3%)	1 (0,9%)	2 (1,3%)	1 (1,6%)	2 (1,8%)	0 (0,0%)	0 (0,0%)	0 (0,0%)
18.5-24.9 (healthy weight)	125 (41,1%)	49 (41,9%)	73 (49,0%)	30 (48,4%)	29 (25,9%)	13 (31,0%)	23 (53,5%)	6 (46,2%)
25.0-29.9 (overweight)	82 (27,0%)	23 (19,7%)	31 (20,8%)	10 (16,1%)	39 (34,8%)	9 (21,4%)	12 (27,9%)	4 (30,8%)
≥30 (obesity)	93 (30,6%)	44 (37,6%)	43 (28,9%)	21 (33,9%)	42 (37,5%)	20 (47,6%)	8 (18,6%)	3 (23,1%)
Smoking, N (%)								
Cigarette user	53 (17,4%)	22 (18,8%)	33 (22,1%)	14 (22,6%)	16 (14,3%)	6 (14,3%)	4 (9,3%)	2 (15,4%)
E-cigarette user	24 (7,9%)	8 (6,8%)	20 (13,4%)	6 (9,7%)	3 (2,7%)	2 (4,8%)	1 (2,3%)	0 (0,0%)
Comorbidities,² N (%)								
Hypertension	39 (12,8%)	11 (9,4%)	13 (8,7%)	4 (6,5%)	18 (16,1%)	6 (14,3%)	8 (18,6%)	1 (7,7%)
Chronic pulmonary disease	33 (10,9%)	17 (14,5%)	13 (8,7%)	6 (9,7%)	14 (12,5%)	10 (23,8%)	6 (14,0%)	1 (7,7%)
Diabetes mellitus	18 (5,9%)	5 (4,3%)	4 (2,7%)	1 (1,6%)	11 (9,8%)	3 (7,1%)	3 (7,0%)	1 (7,7%)
Hypothyroidism	16 (5,3%)	4 (3,4%)	6 (4,0%)	2 (3,2%)	6 (5,4%)	1 (2,4%)	5 (11,6%)	1 (7,7%)
Cancer	10 (3,3%)	3 (2,6%)	4 (2,7%)	1 (1,6%)	5 (4,5%)	2 (4,8%)	1 (2,3%)	0 (0,0%)
Cardiovascular disease	8 (2,6%)	2 (1,7%)	2 (1,3%)	0 (0,0%)	3 (2,7%)	1 (2,4%)	3 (7,0%)	1 (7,7%)
Immune deficiency	7 (2,3%)	5 (4,3%)	3 (2,0%)	3 (4,8%)	1 (0,9%)	0 (0,0%)	3 (7,0%)	2 (15,4%)
Chronic neurological disorder	6 (2,0%)	1 (0,9%)	2 (1,3%)	1 (1,6%)	3 (2,7%)	0 (0,0%)	1 (2,3%)	0 (0,0%)
Liver disease	2 (0,7%)	0 (0,0%)	0 (0,0%)	0 (0,0%)	1 (0,9%)	0 (0,0%)	1 (2,3%)	0 (0,0%)
Blood disorder	1 (0,3%)	1 (0,9%)	1 (0,7%)	1 (1,6%)	0 (0,0%)	0 (0,0%)	0 (0,0%)	0 (0,0%)
Obesity ³	1 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Kidney disease	0 (0,0%)	0 (0,0%)	0 (0,0%)	0 (0,0%)	0 (0,0%)	0 (0,0%)	0 (0,0%)	0 (0,0%)
Influenza vaccination, N (%)								
Usually received	52 (17,1%)	21 (17,9%)	23 (15,4%)	12 (19,4%)	18 (16,1%)	7 (16,7%)	11 (25,6%)	2 (15,4%)
Received in the last year	42 (13,8%)	12 (10,3%)	17 (11,4%)	5 (8,1%)	15 (13,4%)	5 (11,9%)	10 (23,3%)	2 (15,4%)

435 Notes:

436 1. Subset of participants who contracted COVID-19 had least once during the study period.

- 437 2. Comorbidities related to an increased risk of hospitalisation at the first visit.
- 438 3. 30.6% of participants had a BMI in the range of obesity, but only one reported to be obese.

439 **Table 5. Occupational and behavioral characteristic of study participants**

	Overall study population		Restaurant/bar workers		Grocery store workers		Hardware store workers	
	Total (N=304)	COVID-19 ¹ (N=117)	Total (N=149)	COVID-19 ¹ (N=62)	Total (N=112)	COVID-19 ¹ (N=42)	Total (N=43)	COVID-19 ¹ (N=13)
Workplace region,² N (%)								
Capitale-Nationale	240 (78,9%)	96 (82,1%)	123 (82,6%)	49 (79,0%)	85 (75,9%)	36 (85,7%)	32 (74,4%)	11 (84,6%)
Chaudière-Appalaches	64 (21,1%)	19 (16,2%)	26 (17,4%)	12 (19,4%)	27 (24,1%)	6 (14,3%)	11 (25,6%)	1 (7,7%)
Weekly hours worked,³ Mean±SD	27,9 ± 11,5	28,9 ± 11,4	24,7 ± 11,0	24,5 ± 11,0	32,6 ± 10,4	34,2 ± 9,8	26,6 ± 11,9	32,3 ± 10,4
Participants working								
Full time (≥30)	141 (46,4%)	64 (54,7%)	49 (32,9%)	23 (37,1%)	73 (65,2%)	32 (76,2%)	19 (44,2%)	9 (69,2%)
Part time (<30)	163 (53,6%)	53 (45,3%)	100 (67,1%)	39 (62,9%)	39 (34,8%)	10 (23,8%)	24 (55,8%)	4 (30,8%)
Gathering of 10+ persons,³ Mean±SD	17,1 ± 27,5	22,5 ± 31,4	23,2 ± 33,9	31,5 ± 38,9	10,4 ± 15,8	13,1 ± 15,9	13,7 ± 22,1	9,9 ± 10,4
Per group, N (%)								
None	34 (11,2%)	6 (5,1%)	16 (10,7%)	2 (3,2%)	15 (13,4%)	4 (9,5%)	3 (7,0%)	0 (0,0%)
1 to 10 gatherings	146 (48,0%)	47 (40,2%)	57 (38,3%)	16 (25,8%)	62 (55,4%)	22 (52,4%)	27 (62,8%)	9 (69,2%)
11 to 50 gatherings	101 (33,2%)	51 (43,6%)	58 (38,9%)	33 (53,2%)	32 (28,6%)	14 (33,3%)	11 (25,6%)	4 (30,8%)
>50 gatherings	23 (7,6%)	13 (11,1%)	18 (12,1%)	11 (17,7%)	3 (2,7%)	2 (4,8%)	2 (4,7%)	0 (0,0%)
Transportation,² N (%)								
Car	266 (87,5%)	103 (88,0%)	127 (85,2%)	54 (87,1%)	98 (87,5%)	37 (88,1%)	41 (95,3%)	12 (92,3%)
Carpooling	2 (0,7%)	2 (1,7%)	1 (0,7%)	1 (1,6%)	1 (0,9%)	1 (2,4%)	0 (0,0%)	0 (0,0%)
Bus	39 (12,8%)	16 (13,7%)	23 (15,4%)	9 (14,5%)	10 (8,9%)	5 (11,9%)	6 (14,0%)	2 (15,4%)
Bicycle	13 (4,3%)	6 (5,1%)	7 (4,7%)	3 (4,8%)	4 (3,6%)	2 (4,8%)	2 (4,7%)	1 (7,7%)
Walking	28 (9,2%)	11 (9,4%)	13 (8,7%)	6 (9,7%)	14 (12,5%)	5 (11,9%)	1 (2,3%)	0 (0,0%)
Travel,³ N (%)								
Any destination	143 (47,0%)	70 (59,8%)	79 (53,0%)	40 (64,5%)	48 (42,9%)	25 (59,5%)	16 (37,2%)	5 (38,5%)
In Canada	78 (25,7%)	39 (33,3%)	45 (30,2%)	24 (38,7%)	23 (20,5%)	13 (31,0%)	10 (23,3%)	2 (15,4%)
To USA	45 (14,8%)	20 (17,1%)	25 (16,8%)	11 (17,7%)	16 (14,3%)	8 (19,0%)	4 (9,3%)	1 (7,7%)
Other destination ⁴	84 (27,6%)	45 (38,5%)	47 (31,5%)	25 (40,3%)	28 (25,0%)	16 (38,1%)	9 (20,9%)	4 (30,8%)

440 Notes:

441 1. Subset of participants who contracted COVID-19 had least once during the study period.

442 2. At the time of the first visit (i.e., week 0).

443 3. During the entire study period.

444 4. Includes travel to Cuba, Ireland, Great-Britain, Luxembourg, Dominican Republic, South Africa, Bahamas, Morocco, Guadeloupe,

445 Panama, Costa Rica, Greece.

446

447 **Table 6. Protective measures taken at work and elsewhere by study participants at first visit**

	Overall study population		Restaurant/bar workers		Grocery store workers		Hardware store workers	
	Total (N=304)	COVID-19 ¹ (N=117)	Total (N=149)	COVID-19 ¹ (N=62)	Total (N=112)	COVID-19 ¹ (N=42)	Total (N=43)	COVID-19 ¹ (N=13)
Protection measures at work,² N (%)								
Mask	300 (98,7%)	116 (99,1%)	147 (98,7%)	61 (98,4%)	111 (99,1%)	42 (100,0%)	41 (95,3%)	13 (100,0%)
Handwashing	299 (98,4%)	114 (97,4%)	145 (97,3%)	59 (95,2%)	111 (99,1%)	42 (100,0%)	43 (100,0%)	13 (100,0%)
Plexiglas	235 (77,3%)	88 (75,2%)	96 (64,4%)	39 (62,9%)	98 (87,5%)	37 (88,1%)	41 (95,3%)	12 (92,3%)
Social distancing	213 (70,1%)	86 (73,5%)	111 (74,5%)	48 (77,4%)	74 (66,1%)	29 (69,0%)	28 (65,1%)	9 (69,2%)
Protective glasses	77 (25,3%)	12 (10,3%)	30 (20,1%)	4 (6,5%)	35 (31,3%)	5 (11,9%)	12 (27,9%)	3 (23,1%)
Faceshield	32 (10,5%)	4 (3,4%)	16 (10,7%)	1 (1,6%)	13 (11,6%)	2 (4,8%)	3 (7,0%)	1 (7,7%)
Gloves	21 (6,9%)	3 (2,6%)	10 (6,7%)	0 (0,0%)	9 (8,0%)	3 (7,1%)	2 (4,7%)	0 (0,0%)
Face Cover	7 (2,3%)	1 (0,9%)	3 (2,0%)	0 (0,0%)	4 (3,6%)	1 (2,4%)	0 -	0 (0,0%)
Other ³	135 (44,4%)	59 (50,4%)	85 (57,0%)	41 (66,1%)	43 (38,4%)	16 (38,1%)	7 (16,3%)	2 (15,4%)
Behavioral protection measures,² N (%)								
Mask wearing in public spaces	304 (100,0%)	117 (100,0%)	149 (100,0%)	62 (100,0%)	112 (100,0%)	42 (100,0%)	43 (100,0%)	12 (92,3%)
Avoid usual salutations	259 (85,2%)	99 (84,6%)	119 (79,9%)	48 (77,4%)	103 (92,0%)	39 (92,9%)	37 (86,0%)	12 (92,3%)
Social distancing	256 (84,2%)	93 (79,5%)	115 (77,2%)	41 (66,1%)	102 (91,1%)	40 (95,2%)	39 (90,7%)	12 (92,3%)
Avoid contacts with vulnerable persons	254 (83,6%)	93 (79,5%)	114 (76,5%)	42 (67,7%)	100 (89,3%)	38 (90,5%)	40 (93,0%)	13 (100,0%)
Avoid crowded places	233 (76,6%)	81 (69,2%)	102 (68,5%)	35 (56,5%)	94 (83,9%)	34 (81,0%)	37 (86,0%)	12 (92,3%)
Quarantine if exposed to COVID-19	126 (41,4%)	70 (59,8%)	65 (43,6%)	36 (58,1%)	46 (41,1%)	25 (59,5%)	15 (34,9%)	9 (69,2%)
Pre-emptive isolation	36 (11,8%)	23 (19,7%)	21 (14,1%)	13 (21,0%)	12 (10,7%)	9 (21,4%)	3 (7,0%)	1 (7,7%)
Handwashing habits,² N (%)								
After using the toilet	297 (97,7%)	115 (98,3%)	147 (98,7%)	60 (96,8%)	109 (97,3%)	42 (100,0%)	41 (95,3%)	13 (100,0%)
When dirty	294 (96,7%)	113 (96,6%)	140 (94,0%)	58 (93,5%)	112 (100,0%)	42 (100,0%)	42 (97,7%)	13 (100,0%)
When entering workspace	280 (92,1%)	106 (90,6%)	136 (91,3%)	55 (88,7%)	107 (95,5%)	37 (88,1%)	37 (86,0%)	13 (100,0%)
Before eating	267 (87,8%)	104 (88,9%)	124 (83,2%)	51 (82,3%)	105 (93,8%)	41 (97,6%)	38 (88,4%)	12 (92,3%)
Before & after handling food	246 (80,9%)	96 (82,1%)	127 (85,2%)	55 (88,7%)	93 (83,0%)	32 (76,2%)	26 (60,5%)	9 (69,2%)
After handling trash	242 (79,6%)	97 (82,9%)	119 (79,9%)	51 (82,3%)	95 (84,8%)	38 (90,5%)	28 (65,1%)	8 (61,5%)
When exiting workspace	218 (71,7%)	81 (69,2%)	104 (69,8%)	41 (66,1%)	87 (77,7%)	32 (76,2%)	27 (62,8%)	8 (61,5%)
Other ⁴	50 (16,4%)	11 (9,4%)	29 (19,5%)	4 (6,5%)	12 (10,7%)	2 (4,8%)	9 (20,9%)	5 (38,5%)

448 Notes:

449 1. Subset of participants who contracted COVID-19 had least once during the study period

- 450 2. Includes customer registry, QR code, customer limit in store, thorough cleaning of workplace, worker temperature surveillance.
- 451 3. Includes after touching the cash register, handling money, in between clients.

452 **Table 7. Number of COVID-19 positive tests**

	Overall cohort	Bar/ Restaurant	Grocery store	Hardware store
Reported positive COVID-19 tests				
First occurrence	117	62	42	13
PCR	40	24	13	3
Antigen detection	77	38	29	10
Additional test ¹	8	5	2	1
PCR	1	1	0	0
Antigen detection	7	4	2	1
Positive PCR test for COVID-19 at V4 or V5	11	6	5	0
First occurrence	4	1	3	0
Additional test				
<90 days from previous test	4	3	1	0
≥90 days from previous test	3	2	1	0
Reported symptoms (no positive test)	31	17	12	2

453 Notes:

454 1. All 90 days or more since a previously positive test.

455

456 **Table 8. COVID-19 symptoms at the first COVID-19 positive test reported by the participant**

	Overall cohort (N=117)	Bar/ Restaurant (N=62)	Grocery store (N=42)	Hardware store (N=13)
Asymptomatic infection, N (%)	6 (5,1%)	2 (3,2%)	4 (9,5%)	0 (0,0%)
Symptomatic infection, N (%)	111 (94,9%)	60 (96,8%)	38 (90,5%)	13 (100,0%)
Runny nose or nasal congestion	76 (65,0%)	39 (62,9%)	26 (61,9%)	11 (84,6%)
Cough	74 (63,2%)	41 (66,1%)	25 (59,5%)	8 (61,5%)
Headache	71 (60,7%)	36 (58,1%)	26 (61,9%)	9 (69,2%)
Sore throat	70 (59,8%)	41 (66,1%)	23 (54,8%)	6 (46,2%)
Fever	68 (58,1%)	39 (62,9%)	19 (45,2%)	9 (69,2%)
Muscle pain	65 (55,6%)	35 (56,5%)	22 (52,4%)	8 (61,5%)
Shortness of breath	56 (47,9%)	27 (43,5%)	21 (50,0%)	8 (61,5%)
Loss of sense of smell or taste	26 (22,2%)	11 (17,7%)	10 (23,8%)	5 (38,5%)
Diarrhea	16 (13,7%)	7 (11,3%)	8 (19,0%)	1 (7,7%)

457

458 **Table 9. COVID-19 vaccination status at the first reported COVID-19 positive test**

	Overall cohort (N=117)	Bar/ Restaurant (N=62)	Grocery store (N=42)	Hardware store (N=13)
Vaccination status, N (%)				
No vaccine	21 (17.9%)	11 (17.7%)	10 (23.8%)	0 (0.0%)
One dose	1 (0.9%)	0 (0.0%)	1 (2.4%)	0 (0.0%)
Two doses	45 (38.5%)	24 (38.7%)	15 (35.7%)	6 (46.2%)
Three doses	46 (39.3%)	26 (41.9%)	14 (33.3%)	6 (46.2%)
Four doses	4 (3.4%)	1 (1.6%)	2 (4.8%)	1 (7.7%)

459

460 **Table 10. Blood samples collected by vaccination status**

	Overall cohort Blood samples (N = 1299)	
	Infected	Not infected
No Vaccine, N (%)	11 (0.8%)	89 (6.9%)
Vaccinated, N (%)	300 (23.1%)	899 (69.2%)
1 dose	14 (1.1%)	61 (4.7%)
2 doses	145 (11.2%)	584 (45.0%)
3 doses	122 (9.4%)	231 (17.8%)
4 doses	20 (1.5%)	22 (1.7%)

461

Figure 1. Timeline of the study illustrating the visits (colored dash lines) and the first occurrences of COVID-

19-positive tests (grey bars)




Figure 2. Evolution of the vaccination coverage (Comirnaty [Pfizer-BioNTech], SpikeVax [Moderna] or Vaxzevria [AstraZeneca] vaccine) during the study period (A) in the overall cohort stratified by the number of doses received, and (B) stratified by occupational group. The study data are compared to those of the Public Health Agency of Canada (Qc population) for the whole province.²⁰

